- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06048302
PK and Safety in Participants Taking Obicetrapib With Moderate Hepatic Impairment Relative to Normal Hepatic Function
January 20, 2024 updated by: NewAmsterdam Pharma
A Phase 1, Open-label, Single-dose, Parallel-group Study to Evaluate the Plasma Pharmacokinetics and Safety of Obicetrapib in Participants With Moderate Hepatic Impairment Relative to Participants With Normal Hepatic Function
To investigate the safety and pharmacokinetics in patients with moderate hepatic impairment compared to healthy participants after a single oral dose of obicetrapib (10 mg).
Study Overview
Detailed Description
This is a Phase 1, open-label, single-dose, parallel-group study to evaluate the plasma PK and safety of obicetrapib in participants with moderate hepatic impairment relative to participants with normal hepatic function.
The purpose of the study is to investigate the effect of moderate hepatic impairment on obicetrapib PK and safety in otherwise healthy participants after a single oral 10 mg dose of obicetrapib.
Study Type
Interventional
Enrollment (Estimated)
16
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Minnesota
-
Saint Paul, Minnesota, United States, 55114
- Recruiting
- Nucleus Network
-
Contact:
- Jennifer Bookley
- Phone Number: 651-641-2900
- Email: Trisha Shamp <t.shamp@nucleusnetwork.com>
-
-
Texas
-
San Antonio, Texas, United States, 78215
- Recruiting
- The American Research Corporation
-
Contact:
- Haylee Schulmeier
- Phone Number: 210-253-3426
- Email: hschulmeier@txliver.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- A male or a female of non-childbearing potential.
- Women of childbearing potential (WOCBP) must have a negative serum beta-human chorionic gonadotropin (β-hCG) pregnancy test at the Screening Visit.
- Body mass index (BMI) of 17.5 to 42 kg/m2; with a total body weight >50 kg (110 lb).
- Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the ICF and in this protocol.
- Willing and able to comply with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations, and other study procedures.
- Cohort 1: Meet the criteria for Class B (moderate hepatic impairment) of the modified CPC. A diagnosis of hepatic dysfunction due to hepatocellular disease (and not secondary to any acute ongoing hepatocellular process) documented by medical history, physical examination (PE), liver biopsy, hepatic ultrasound, computerized tomography scan, or magnetic resonance imaging.
- Cohort 2: Will only enroll healthy volunteers with no hepatic impairment. "Healthy" is defined as no clinically relevant abnormalities identified by a detailed medical history, complete PE (including blood pressure [BP] and pulse rate measurement), 12-lead ECG or clinical laboratory tests performed during Screening.
Exclusion Criteria:
- Any condition possibly affecting drug absorption (e.g., gastrectomy). Uncomplicated cholecystectomy is allowed.
- History of or current positive results for human immunodeficiency virus (HIV) infection, hepatitis B virus (HBV) or hepatitis C virus (HCV), including hepatitis B surface antigen (HbsAg) or hepatitis C Virus antibody (HCVAb).
- Other medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the Investigator's judgment, make the participant inappropriate for participation in the study.
- Participants with an estimated glomerular filtration rate (eGFR) value of ≤30 mL/min/1.73 m2, based on the 2021 Chronic Kidney Disease Epidemiology Collaboration equation during Screening. A single repeat assessment is permitted to assess eligibility, if needed.
- Previous administration of drugs or supplements known to be strong inducers or inhibitors of CYP3A4 within 7 days of planned dosing of obicetrapib on Day 1.
- Concurrent use of drugs or supplements that are known substrates of CYP3A that have narrow therapeutic indices (e.g., alfentanil, cyclosporine, dihydroergotamine, ergotamine, fentanyl including transdermal patch, pimozide, quinidine, sirolimus, tacrolimus) within 12 days prior to planned dosing of obicetrapib on Day 1.
- Participants on oral contraceptives and hormonal based contraceptives including implantable, intrauterine, intravaginal, transdermal or injectable form.
- Previous administration of an investigational drug within 30 days (or as determined by the local requirement) or within 5 half-lives of that investigational drug, prior to planned dosing of obicetrapib on Day 1.
- Known hypersensitivity to obicetrapib or its excipients.
- A positive urine drug test. Participants with moderate hepatic impairment (Cohort 1) will be eligible to participate if their urine drug test is positive with a drug for a prescribed condition that is not expected to interfere with the PK of obicetrapib. Positive urine drug tests for tetrahydrocannabinol (THC) will be allowed as long as the volunteer agrees to abstain from ingesting any THC-containing products for the duration of the study (including Out patient visits up to Day 28).
- Blood donation (excluding plasma donations) of approximately 1 pint (500 mL) or more within 60 days prior to planned dosing of obicetrapib on Day 1.
- History of sensitivity to heparin or a history of heparin-induced thrombocytopenia.
- Unwilling or unable to comply with the criteria in the Lifestyle considerations listed in the protocol.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Active Comparitor: Subjects with Moderate Hepatic Impairment
8 patients with hepatic impairment of moderate Child Pugh Category
|
1 single dose of obicetrapib
Other Names:
|
Other: Active Comparator: Healthy Subjects
Healthy volunteers will be matched with impaired hepatic function patients
|
1 single dose of obicetrapib
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Area under the curve from dosing time to infinity (AUC (0-inf)) for obicetrapib
Time Frame: 0 (pre-dose), 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 48, 72, 120, 168
|
Blood samples collected
|
0 (pre-dose), 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 48, 72, 120, 168
|
Area under curve from dosing time to last measurement (AUC (0-t)) for obicetrapib
Time Frame: 0 (pre-dose), 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 48, 72, 120, 168
|
Blood Sample Collected
|
0 (pre-dose), 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 48, 72, 120, 168
|
Observed maximum plasma concentration (Cmax) for Obicetrapib
Time Frame: 0 (pre-dose), 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 48, 72, 120, 168
|
Blood Sample Collected
|
0 (pre-dose), 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 48, 72, 120, 168
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 30, 2023
Primary Completion (Estimated)
May 31, 2024
Study Completion (Estimated)
July 30, 2024
Study Registration Dates
First Submitted
August 29, 2023
First Submitted That Met QC Criteria
September 15, 2023
First Posted (Actual)
September 21, 2023
Study Record Updates
Last Update Posted (Actual)
January 23, 2024
Last Update Submitted That Met QC Criteria
January 20, 2024
Last Verified
August 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- TA-8995-12
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on Obicetrapib
-
NewAmsterdam PharmaMonash UniversityRecruitingAtherosclerotic Cardiovascular DiseaseUnited States, Israel, Italy, Spain, Canada, Czechia, Poland, China, Denmark, Netherlands, Finland, Japan, Australia, Hungary, Germany, Croatia, United Kingdom, Bulgaria, South Africa, Georgia, Jordan, Slovakia, Latvia
-
NewAmsterdam PharmaActive, not recruitingDyslipidemias | Hypercholesterolemia | Familial Hypercholesterolemia | Atherosclerotic Cardiovascular Disease | High CholesterolUnited States, Poland, Denmark, Czechia, China, Netherlands, Japan, Georgia
-
NewAmsterdam PharmaCompletedEarly Alzheimer's DiseaseNetherlands
-
NewAmsterdam PharmaActive, not recruitingDyslipidemias | Hypercholesterolemia | Hyperlipoproteinemias | Lipid Metabolism, Inborn Errors | Familial Hypercholesterolemia | Metabolic Disease | High Cholesterol | Genetic Disease, Inborn | Lipid Metabolism DisorderUnited States, Canada, Czechia, Georgia, Netherlands, Norway, Poland, South Africa, Spain, United Kingdom
-
NewAmsterdam PharmaUniversity of PennsylvaniaRecruiting
-
NewAmsterdam PharmaRecruitingDyslipidemias | Hypercholesterolemia | Familial Hypercholesterolemia | High Cholesterol | ASCVDUnited States
-
NewAmsterdam PharmaCompletedDyslipidemias | Hypercholesterolemia | High CholesterolUnited States
-
NewAmsterdam PharmaCompletedDyslipidemias | Hypercholesterolemia | High CholesterolUnited States
-
NewAmsterdam PharmaCompletedDyslipidemia | Hypercholesterolemia | High CholesterolJapan
-
NewAmsterdam PharmaNot yet recruitingCoronary Artery Disease | Plaque, Atherosclerotic | Lipidemia